The center will be located in Buji Lilang, with a construction area of ​​about 150,000 square meters. After completion, it will have 1,100 wards and 2,500 beds. It will be financed by China Gene Group (Hong Kong) in cooperation with Luohu Hospital Group and focus on rare diseases such as GM2 gangliosidosis and diseases which are difficult to treat such as senile dementia and leukemia. China Gene Group (Hong Kong) plans for a total investment of about 2 billion yuan.

China Bio news release, August 17, 2018